HCC updates from ILCA and ESMO congressess 2022

Episode 1 October 06, 2022 00:30:22
HCC updates from ILCA and ESMO congressess 2022
COR2ED Medical Education
HCC updates from ILCA and ESMO congressess 2022

Oct 06 2022 | 00:30:22

/

Show Notes

COR2ED Medical Education: In this HCC CONNECT podcast HCC Experts Prof. Matthias Pinter and Prof. Jeroen Dekervel, discuss and debate the clinical implications of new HCC Phase 3 clinical trials data presented and discussed at the ILCA and ESMO congresses. They discuss Immuno-oncology agents and their place in the upcoming updated guidance such as the proposed new ILCA Systemic Therapies Guidance algorithm. They also discuss new treatment options in first line for advanced HCC presented at ESMO including the three late breaking abstracts LEAP-002, RATIONALE-301 and tislelizumab monotherapy trials. The latter two studying first-line treatment with an anti-PD1 antibody with or without a kinase inhibitor in patients with advanced hepatocellular carcinoma. The experts evaluate and provide their insights into how to integrate these new treatments for HCC in the clinical practice.

Other Episodes

Episode 1

October 13, 2021 00:20:43
Episode Cover

Choosing the Best Treatment Regimen in Multiple Myeloma: Episode 1 - the Newly Diagnosed Setting

In this medical education podcast series, myeloma experts Dr. Joshua Richter (Assistant Professor of Medicine and Director of Myeloma at the Tisch Cancer Institute...

Listen

Episode 2

February 15, 2023 00:19:43
Episode Cover

PARPi and NHA combination therapy for patients with mCRPC – a US and EU perspective

COR2ED Medical Education: Dr Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States and...

Listen

Episode 3

April 05, 2023 00:22:48
Episode Cover

Case-based discussion on which mCSPC patients benefit from early treatment intensification

COR2ED Medical Education: Assoc. Prof. Shilpa Gupta and Dr Fabio Schutz, discuss early treatment intensification with triplet therapy for metastatic castration-sensitive prostate cancer (mCSPC)...

Listen